These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 7629807)

  • 1. Prediction of drug binding affinities by comparative binding energy analysis.
    Ortiz AR; Pisabarro MT; Gago F; Wade RC
    J Med Chem; 1995 Jul; 38(14):2681-91. PubMed ID: 7629807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reliability of comparative molecular field analysis models: effects of data scaling and variable selection using a set of human synovial fluid phospholipase A2 inhibitors.
    Ortiz AR; Pastor M; Palomer A; Cruciani G; Gago F; Wade RC
    J Med Chem; 1997 Mar; 40(7):1136-48. PubMed ID: 9089335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational modification of human synovial fluid phospholipase A2 inhibitors.
    Pisabarro MT; Ortiz AR; Palomer A; Cabré F; García L; Wade RC; Gago F; Mauleón D; Carganico G
    J Med Chem; 1994 Feb; 37(3):337-41. PubMed ID: 8308860
    [No Abstract]   [Full Text] [Related]  

  • 4. A molecular dynamics study of the three-dimensional model of human synovial fluid phospholipase A2--transition state mimic complexes.
    Hariprasad V; Kulkarni VM
    J Mol Recognit; 1996; 9(2):95-102. PubMed ID: 8877799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-dimensional structures of human phospholipase A2 from pancreas and synovial fluid by model building.
    Christensen IT; Jørgensen FS; Svensson LA; Högberg T
    Drug Des Discov; 1993 Jun; 10(2):101-13. PubMed ID: 8399996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physics-based methods for studying protein-ligand interactions.
    Huang N; Jacobson MP
    Curr Opin Drug Discov Devel; 2007 May; 10(3):325-31. PubMed ID: 17554859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative binding energy analysis of HIV-1 protease inhibitors: incorporation of solvent effects and validation as a powerful tool in receptor-based drug design.
    Pérez C; Pastor M; Ortiz AR; Gago F
    J Med Chem; 1998 Mar; 41(6):836-52. PubMed ID: 9526559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of ligand-receptor binding thermodynamics by free energy force field three-dimensional quantitative structure-activity relationship analysis: applications to a set of glucose analogue inhibitors of glycogen phosphorylase.
    Venkatarangan P; Hopfinger AJ
    J Med Chem; 1999 Jun; 42(12):2169-79. PubMed ID: 10377222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibodies against human synovial phospholipase A2.
    Takayama K; Kudo I; Hara S; Murakami M; Matsuta K; Miyamoto T; Inoue K
    Biochem Biophys Res Commun; 1990 Mar; 167(3):1309-15. PubMed ID: 2322277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based and multiple potential three-dimensional quantitative structure-activity relationship (SB-MP-3D-QSAR) for inhibitor design.
    Du QS; Gao J; Wei YT; Du LQ; Wang SQ; Huang RB
    J Chem Inf Model; 2012 Apr; 52(4):996-1004. PubMed ID: 22480344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment and acceleration of binding energy calculations for protein-ligand complexes by the fragment molecular orbital method.
    Otsuka T; Okimoto N; Taiji M
    J Comput Chem; 2015 Nov; 36(30):2209-18. PubMed ID: 26400829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of ligand-receptor binding thermodynamics by free energy force field (FEFF) 3D-QSAR analysis: application to a set of peptidometic renin inhibitors.
    Tokarski JS; Hopfinger AJ
    J Chem Inf Comput Sci; 1997; 37(4):792-811. PubMed ID: 9254912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human synovial fluid phospholipase A2 and N-terminal variant: kinetic parameters and response to inhibitors.
    Märki F; Hanulak V
    J Biochem; 1993 Jun; 113(6):734-7. PubMed ID: 8370672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular dynamics study of phospholipase A2 on a membrane surface.
    Zhou F; Schulten K
    Proteins; 1996 May; 25(1):12-27. PubMed ID: 8727316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of ligand binding affinity and orientation of xenoestrogens to the estrogen receptor by molecular dynamics simulations and the linear interaction energy method.
    van Lipzig MM; ter Laak AM; Jongejan A; Vermeulen NP; Wamelink M; Geerke D; Meerman JH
    J Med Chem; 2004 Feb; 47(4):1018-30. PubMed ID: 14761204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A swift all-atom energy-based computational protocol to predict DNA-ligand binding affinity and DeltaTm.
    Shaikh SA; Jayaram B
    J Med Chem; 2007 May; 50(9):2240-4. PubMed ID: 17419602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substrate specificity in short-chain phospholipid analogs at the active site of human synovial phospholipase A2.
    Wheeler TN; Blanchard SG; Andrews RC; Fang F; Gray-Nunez Y; Harris CO; Lambert MH; Mehrotra MM; Parks DJ; Ray JA
    J Med Chem; 1994 Nov; 37(24):4118-29. PubMed ID: 7990112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular modeling of hydration in drug design.
    Mancera RL
    Curr Opin Drug Discov Devel; 2007 May; 10(3):275-80. PubMed ID: 17554853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling of substrate and inhibitor binding to phospholipase A2.
    Sessions RB; Dauber-Osguthorpe P; Campbell MM; Osguthorpe DJ
    Proteins; 1992 Sep; 14(1):45-64. PubMed ID: 1409562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular model of the interaction of bee venom phospholipase A2 with manoalide.
    Ortiz AR; Pisabarro MT; Gago F
    J Med Chem; 1993 Jun; 36(13):1866-79. PubMed ID: 8515424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.